Tune into the HTG Molecular Diagnostics 2015 Third Quarter Financial Results Conference Call on November 12, 2015 and HTG’s Presentation at Canccord on November 19, 2016 via webcasts.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) is a provider of instruments and reagents for molecular profiling applications. In October 2015, HTG Molecular Diagnostics was honored with AZBio’s Fast Lane Award in recognition of its contribution to new innovations and tools in the field of molecular diagnostics for the advancement of precision medicine. This November, members of the community can tune in to get the latest up dates from HTG Molecular’s leadership.
The Company will release 2015 third quarter financial results after market close on Thursday, November 12, 2015. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, November 12 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 52349679), or from the webcast on the “Investors” section of the Company’s website at: http://www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
The following week, HTG Molecular Diagnostics will be presenting at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 19, 2015 in New York.
HTG management is scheduled to present at 2:00 p.m. ET. A live audio webcast of the presentation can be accessed by visiting the “Investors” section of HTG’s website at: http://www.htgmolecular.com. The webcast will be available on HTG’s website for 90 days following the completion of the presentation.
Q3 2015 HTG Molecular Diagnostics Inc Earnings Conference Call (Live)
11/12/15 at 1:30 p.m. PT (12:30 in AZ)
HTG Molecular Diagnostics Inc at Canaccord Genuity 2015 Medical Technologies & Diagnostics Forum (Live)
11/19/15 at 2:00 p.m. ET (Noon in AZ)
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.